A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer (TARGET-D 203)
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Verastem Call Center
- Telefonnummer: 7812924204
- E-mail: VS-7375-203TrialSupport@verastem.com
Undersøgelse Kontakt Backup
- Navn: Bina Tejura, MD
- E-mail: VS-7375-203Medical@verastem.com
Studiesteder
-
-
New South Wales
-
Macquarie Park, New South Wales, Australien, 2109
- Rekruttering
- Macquarie University Hospital
-
Kontakt:
- Sam Ly
- Telefonnummer: +612 9812 3538
- E-mail: sam.ly@mq.edu.au
-
Kontakt:
- Jignasa Mahida
- Telefonnummer: +61 466 476 498
- E-mail: Jignasa.mahida@mq.edu.au
-
Ledende efterforsker:
- Andrew Parsonson, MBBS MMed (Clin Epi) FRACP
-
Waratah, New South Wales, Australien, 2298
- Rekruttering
- Calvary Mater Newcastle
-
Ledende efterforsker:
- Girish Mallesara, MBBS, MD, DM, FRACP
-
Kontakt:
- Kerrie Cornall
- Telefonnummer: 02 4014 3290
- E-mail: Kerrie.Cornall@health.nsw.gov.au
-
-
Queensland
-
Hyde Park, Queensland, Australien, 4812
- Rekruttering
- Icon Cancer Centre Townsville
-
Kontakt:
- Peyman Halvaeikhanekahdani
- Telefonnummer: 61747957100
- E-mail: peyman.halvaeikhanekahdani@icon.team
-
Ledende efterforsker:
- Abhishek Joshi, MBBS, MD, DM, FRACP
-
South Brisbane, Queensland, Australien, 4101
- Rekruttering
- Icon Cancer Centre South Brisbane
-
Ledende efterforsker:
- Jermaine Coward, MBBS, MRCP (UK), FRACP, PhD
-
Kontakt:
- Apryl Chelin
- Telefonnummer: 07 3737 4700
- E-mail: Apryl.chelin@icon.team
-
-
South Australia
-
Kurralta Park, South Australia, Australien, 5037
- Rekruttering
- Icon Cancer Centre Adelaide
-
Ledende efterforsker:
- Carolyn Bampton, MBBS, FRACP
-
Kontakt:
- Icon Cancer Centre Adelaide/Kurralta Park
- Telefonnummer: 08 8474 0220
- E-mail: EthicsCoordinator@icon.team
-
-
Tasmania
-
Hobart, Tasmania, Australien, 7000
- Rekruttering
- Icon Cancer Centre Hobart
-
Kontakt:
- Icon Cancer Centre Hobart
- Telefonnummer: 03 6240 2600
- E-mail: hobart.research@icon.team
-
Ledende efterforsker:
- Louise Nott, BMedSci, MBBS(Hons), FRACP
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Rekruttering
- Alfred Hospital
-
Kontakt:
- Ben Markman, MBBS (Hons), FRACP
- Telefonnummer: 390763129
- E-mail: ben.markman@monash.edu
-
Kontakt:
- Kate Sinn
- Telefonnummer: 390760569
- E-mail: K.Sinn@alfred.org.au
-
Ledende efterforsker:
- Ben Markman, MBBS (Hons), FRACP
-
-
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85258
- Rekruttering
- HonorHealth
-
Ledende efterforsker:
- Sunil Sharma, MD
-
Kontakt:
- Sunil Sharma, MD
- Telefonnummer: 480-323-1350
- E-mail: ssharma@honorhealth.com
-
-
California
-
Los Angeles, California, Forenede Stater, 90048
- Rekruttering
- Cedars-Sinai Medical Center
-
Kontakt:
- Cedars-Sinai Trial Information
- Telefonnummer: 1-800-233-2771
- E-mail: GroupCancerTrialInformation@cshs.org
-
Ledende efterforsker:
- Jun Gong, MD
-
Los Angeles, California, Forenede Stater, 90025
- Rekruttering
- START Los Angeles
-
Kontakt:
- START Hope Team
- Telefonnummer: 424-465-1820
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Navid Hafez, M.D., MPH
-
Los Angeles, California, Forenede Stater, 90067
- Rekruttering
- Valkyrie Clinical Trials (contact for more locations)
-
Ledende efterforsker:
- David Berz, MD, PhD, MPH
-
Kontakt:
- Trenis Palmer, PhD
- Telefonnummer: 912-398-3205
- E-mail: trenis.palmer@vctcare.com
-
-
Florida
-
Coral Springs, Florida, Forenede Stater, 33065
- Rekruttering
- BRCR - Coral Springs
-
Ledende efterforsker:
- Sumit Sawhney, MD
-
Kontakt:
- Sumit Sawhney, MD
- Telefonnummer: 561-447-0614
- E-mail: ssawhney.md@brcrglobal.com
-
Tamarac, Florida, Forenede Stater, 33321
- Rekruttering
- BRCR - Tamarac
-
Ledende efterforsker:
- Andrew Schneider, MD
-
Kontakt:
- Diana Casas
- Telefonnummer: 561-447-0614
- E-mail: dianac@brcrglobal.com
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
Ledende efterforsker:
- Tiago Biachi de Castria, MD, PhD
-
Kontakt:
- Cheyenne Schneider
- Telefonnummer: 813-745-3691
- E-mail: Cheyenne.Schneider@moffitt.org
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Indiana University, Simon Comprehensive Cancer Center
-
Kontakt:
- Yvonne LaFary
- Telefonnummer: 317-278-5613
- E-mail: ylafary@iu.edu
-
Ledende efterforsker:
- Anita Turk, M.D.
-
-
Michigan
-
Grand Rapids, Michigan, Forenede Stater, 49546
- Rekruttering
- START Midwest
-
Kontakt:
- START Hope Team
- Telefonnummer: 616-954-5554
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Sreenivasa R Chandana, M.D., Ph.D.
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University
-
Ledende efterforsker:
- Kian-Huat Lim, M.D., Ph.D.
-
Kontakt:
- Caroline Bumb
- Telefonnummer: 314-747-4000
- E-mail: cbumb@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Forenede Stater, 08816
- Rekruttering
- START New Jersey
-
Kontakt:
- START Hope Team
- Telefonnummer: 732-426-4750
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Bruno S Fang, M.D.
-
-
New York
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- Perlmutter Cancer Center at NYU Langone Health (contact for more locations)
-
Kontakt:
- Rafael Winograd, MD, PhD
- Telefonnummer: 646-501-7802
- E-mail: CancerTrials@nyulangone.org
-
Ledende efterforsker:
- Rafael Winograd, MD, PhD
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- University of North Carolina
-
Kontakt:
- Catherine Griffin
- Telefonnummer: 919-966-4432
- E-mail: catherine_griffin@med.unc.edu
-
Ledende efterforsker:
- Michael Iglesia, MD, PhD
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- Case Western, University Hospitals Cleveland Medical Center
-
Ledende efterforsker:
- Amit Mahipal, MD
-
Kontakt:
- Amit Mahipal, MD
- Telefonnummer: (216)844-6031
- E-mail: Amit.Mahipal@UHhospitals.org
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Sarah Cannon Research Institute Oncology Partners
-
Ledende efterforsker:
- Meredith Pelster, MD
-
Kontakt:
- ASK SARAH
- Telefonnummer: 877-691-7274
- E-mail: askSARAH@scresearch.net
-
-
Texas
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- START Dallas Fort Worth
-
Kontakt:
- START Hope Team
- Telefonnummer: 682-350-3010
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- Salwan Al Mutar, M.D., M.Sc.
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- The University of Texas MD Anderson Cancer Center
-
Ledende efterforsker:
- Christine Parseghian, MD
-
Kontakt:
- MD Anderson Cancer Center, GI Medical Oncology Dept
- Telefonnummer: 855-982-0789
- E-mail: GIClinicalTrials@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84112
- Rekruttering
- Huntsman Cancer Institute - University of Utah
-
Ledende efterforsker:
- Christopher Nevala-Plagemann, MD
-
Kontakt:
- Susan Sharry
- Telefonnummer: 801-585-3453
- E-mail: susan.sharry@hci.utah.edu
-
West Valley City, Utah, Forenede Stater, 84119
- Rekruttering
- START Mountain Region
-
Kontakt:
- START Hope Team
- Telefonnummer: 801-907-4750
- E-mail: hopeteam@startresearch.com
-
Ledende efterforsker:
- José M Pacheco, M.D.
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- Rekruttering
- UVA Comprehensive Cancer Center
-
Ledende efterforsker:
- Matthew Reilley, MD
-
Kontakt:
- Clinical Trials Navigator
- Telefonnummer: 434-982-0539
- E-mail: UVACANCERTRIALS@uvahealth.org
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Virginia Cancer Specialists
-
Kontakt:
- VCS Research Referrals
- Telefonnummer: 703-636-1473
- E-mail: vcsresearchreferrals@usoncology.com
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98101
- Rekruttering
- Virginia Mason Medical Center
-
Kontakt:
- Cancer Research Team
- Telefonnummer: 206-287-6270
- E-mail: crp@benaroyaresearch.org
-
Ledende efterforsker:
- Jessica Lee, DO
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- Rekruttering
- University of Wisconsin
-
Ledende efterforsker:
- Dustin Deming, MD
-
Kontakt:
- UW Cancer Connect
- Telefonnummer: 800-622-8922
- E-mail: cancerconnect@uwhealth.org
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Histopathology confirmed metastatic CRC
-
Measurable disease per RECIST 1.1
-
Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
-
ECOG PS=0 or 1
2L+ patients:
-
Must have received at least 1 standard chemotherapy for metastatic colorectal adenocarcinoma
-
Have documented disease progression during or following their most recent prior line of therapy
-
Have either stable disease, partial response (PR), or complete response (CR) by RECIST v1.1 as the best overall response (BOR) during at least 1 prior systemic therapy.
1L patients:
-
Treatment-naïve or received no more than 1 cycle of standard systemic therapy for metastatic disease.
Exclusion Criteria:
- Have any other documented co-existing common RAS mutation(s)
- Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
- Major surgery within 4 weeks of first treatment dose
- Radiation therapy (RT) within 1 week of first treatment dose
- Receipt of prior direct RAS inhibitor
- Receipt of more than 1 investigational therapy
- Untreated or symptomatic CNS metastasis
- Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
- Receipt of PPI or H2 blocker within 5 days
- Inability to swallow oral medication
- Other protocol-defined inclusion/exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: VS-7375 with chosen regimen in 2L+ CRC
|
Taken by mouth Intravenous infusion Intravenous infusion |
|
Eksperimentel: VS-7375 + cetuximab and mFOLFOX in 1L CRC
|
Intravenous infusion |
|
Eksperimentel: VS-7375 Monotherapy or Preferred Combination in 2L+ CRC
Participants randomized to a treatment in 2:1 ratio |
Taken by mouth Intravenous infusion Intravenous infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only
Tidsramme: 6 months
|
Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR) |
6 months
|
|
To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC
Tidsramme: 6 months
|
Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations |
6 months
|
|
To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC
Tidsramme: 6 months
|
Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations |
6 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, Cmax
Tidsramme: 20 weeks
|
Maximum concentration (Cmax) |
20 weeks
|
|
Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, AUC
Tidsramme: 20 weeks
|
Area under plasma Concentration (AUC) 0 to t |
20 weeks
|
|
To evaluate Pharmacodynamics (PD) and other relevant blood tumor markers specific to tumor type
Tidsramme: Up to 2.5 years
|
CA19-9, CEA, CA-125 |
Up to 2.5 years
|
|
Time to next therapy
Tidsramme: 24 months
|
To assess the interval between initiation of study treatment and initiation of subsequent treatment |
24 months
|
|
Confirmed ORR per RECIST v1.1 assessed by BICR (primary) and Investigator (secondary) assessments
Tidsramme: 24 months
|
To evaluate additional efficacy parameters of VS-7375 monotherapy and VS-7375 in combination with cetuximab or panitumumab or cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated CRC |
24 months
|
|
To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30)
Tidsramme: 24 months
|
The EORTC QLQ-C30 is a validated questionnaire to assess the quality of life of colorectal cancer patients |
24 months
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Imaging of tumor metabolism changes in 2L monotherapy patients
Tidsramme: 24 months
|
To assess tumor metabolism dynamics on FDG-PET/CT |
24 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Tyktarmssygdomme
- Kolorektale neoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Panitumumab
- Cetuximab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- VS-7375-203
- 2026-526473-42-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .